Qualigen Files US Application To Start Human Trials For COVID-19 Candidate

Qualigen Files US Application To Start Human Trials For COVID-19 Candidate
  • Qualigen Therapeutics Inc QLGN has submitted an Investigational New Drug (IND) application to the FDA for its QN-165 with an initial target indication of COVID-19 in hospitalized patients. 
  • QN-165, a DNA aptamer, is a broad-based antiviral drug candidate that has exhibited antiviral activity in multiple in vitro assays against different viruses.
  • Price Action: QLGN shares are up 10.1% at $1.96 during the premarket session on the last check Wednesday.
  • Related content: Benzinga's Full FDA Calendar.
Posted In: BriefsCovid-19BiotechNewsPenny StocksHealth CareFDAGeneral